GleamWall
中文EN

KAPA Kairos Pharma, LTD.

Pharmaceutical Preparations · NYSE · SEC CIK 1962011 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-26.3%
TTM EPS YoY83.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-110.8%
ROA-102.8%
ROIC (approx.)-363.5%
Asset turnover—

Leverage & solvency

Liabilities / assets11.3%
Debt / equity0.00x
Current ratio6.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.64x
Accruals ratio-36.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$892,000$619,000$684,000$538,000$608,000$496,000$493,000$172,000
SG&A expense$1.12M$798,000$1.01M$877,000$827,000$960,000$773,000$1.27M
Operating income-$2.01M-$1.42M-$1.69M-$1.42M-$1.44M-$1.46M-$1.27M-$1.45M
Interest expense———————$0
Net income-$1.98M-$1.39M-$1.65M-$1.36M-$1.40M-$1.42M-$1.26M-$980,000
EPS (basic)-0.59-0.06-0.08—-0.48-0.08-0.08—
EPS (diluted)-0.59-0.06-0.08—-0.48-0.08-0.08—
Weighted avg. shares (diluted)3.35M21.42M21.01M—2.89M17.21M15.88M—
Balance sheet
Cash & equivalents$3.12M$2.63M$3.67M$4.49M$5.58M$3.03M$3.62M$1.27M
Current assets$3.35M$3.17M$4.44M$5.39M$6.66M$4.84M$6.05M$4.17M
Intangibles—$191,000$22,000$62,000$102,000$142,000$182,000$222,000
Total assets$4.37M$4.46M$5.74M$6.54M$8.07M$6.67M$7.94M$5.77M
Current liabilities$495,000$265,000$431,000$199,000$402,000$676,000$805,000$992,000
Total liabilities$495,000$265,000$431,000$199,000$402,000$676,000$805,000$992,000
Shareholders' equity$3.88M$4.19M$5.31M$6.34M$7.66M$6.00M$7.13M$4.78M
Shares outstanding3.73M21.42M21.41M2.97M20.82M17.74M15.83M13.74M
Cash flow statement
Operating cash flow-$979,000-$1.01M-$1.04M-$1.08M-$838,000-$805,000-$714,000-$1.80M
Financing cash flow$1.48M-$37,000$220,000$0$3.38M$223,000$3.06M-$142,000

Free plan shows the latest 8 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.